Ultimovacs Q2 2023: Minor trial delays but investment case intact - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Ultimovacs Q2 2023: Minor trial delays but investment case intact - Redeye

{newsItem.title}

Redeye comments on Ultimovacs’ Q2 2023 report, following a quarter in which the company’s share price took a hit due to inconclusive NIPU top-line data. We judge INITIUM top-line data in H1 2024e and more detailed NIPU data in Q4 2023e could provide critical catalysts for the share. We make minor changes in our valuation model.

Länk till analysen i sin helhet: https://www.redeye.se/research/936413/ultimovacs-q2-2023-minor-trial-delays-but-investment-case-intact?utm_source=finwire&utm_medium=RSS

Nyheter om Ultimovacs

Läses av andra just nu

Om aktien Ultimovacs

Senaste nytt